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Abstract
The mature F protein of all known isolates of human respiratory syncytial virus (HRSV) contains
fifteen absolutely conserved cysteine (C) residues that are highly conserved among the F proteins
of other pneumoviruses as well as the paramyxoviruses. To explore the contribution of the
cysteines in the extracellular domain to the fusion activity of HRSV F protein, each cysteine was
changed to serine. Mutation of cysteines 37, 313, 322, 333, 343, 358, 367, 393, 416, and 439
abolished or greatly reduced cell surface expression suggesting these residues are critical for
proper protein folding and transport to the cell surface. As expected, the fusion activity of these
mutations was greatly reduced or abolished. Mutation of cysteine residues 212, 382, and 422 had
little to no effect upon cell surface expression or fusion activity at 32°C, 37°C, or 39.5°C. Mutation
of C37 and C69 in the F2 subunit either abolished or reduced cell surface expression by 75%
respectively. None of the mutations displayed a temperature sensitive phenotype.
Background
Infection by HRSV is the single most common cause of
hospitalization of infants and young children due to
bronchiolitis and pneumonia and is a significant cause of
morbidity and mortality the elderly and transplant recipi-
ents [1-4]. HRSV is member of the subfamily Pneumoviri-
nae in the Paramyxoviridae family (reviewed in [5]. Three
viral transmembrane proteins (F, G, and SH) are present
on the surface of the virion particle [6]. The SH and G pro-
teins are not required for virus replication in culture,
although recombinant viruses lacking these genes are
attenuated in animals [7-13]. The F protein is a type 1
membrane protein required for the fusion of the viral and
host cell membranes as well as the formation of mature
virion particles [10,14-16]. The HRSV F mRNA is trans-
lated into a 574 amino acid precursor protein designated
F0, which contains a signal peptide sequence at the N-ter-
minus that is removed by a signal peptidase in the endo-
plasmic reticulum (ER) [17-21]. F0 is contains 5 or 6 N-
linked glycosylation sites depending upon virus strain
[5,22,23]. F0 is cleaved at two sites [24] by furin in the
trans-Golgi [18,19] removing a short, glycosylated inter-
vening sequence and generating two subunits designated
F1 (~50 kDa) that contains a single N-linked glycosyla-
tion site and F2 (~20 kDa) which contains two N-linked
glycosylation sites [20]. The F1 and F2 chains are joined
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together by disulfide bond formation [25,26] although it
has not been formally demonstrated which specific resi-
dues mediate this. The mature form of the F protein
present on the surface of the virus and infected cells is
believed to consist of a homotrimer consisting of three
non-covalently associated units of F1-F2. This trimer has
recently been shown to be quite thermostable [27]. Simi-
lar to other type I membrane viral fusion proteins
(reviewed in [28], the F1 subunit contains a hydrophobic
fusion peptide region followed by two heptad repeat
regions (HR1 and HR2) that are separated by an interven-
ing cysteine-rich region. A hydrophobic transmembrane
domain is located near the C-terminus of the protein fol-
lowed by a short (26 residues) cytoplasmic domain con-
taining a single cysteine residue (Figure 1). Similar to
other viral fusion proteins, F-mediated fusion with the
host cell membrane is believed to be mediated by inser-
tion of the fusion peptide into the host cytoplasmic mem-
brane followed by subsequent conformational changes
resulting in the interaction of the HR1 and HR2 regions,
and the formation of a 6-helix bundle structure [29-31].
This process brings the viral membrane and host cell
membrane in close proximity with each other allowing for
lipid mixing and the fusion of the two membranes.
Although a structure of the crystal of the HRSV F protein
6-helix bundle has been determined [31] and electron
microscopy images of HRSV F protein have been
described [32], no detailed structural information for the
entire protein exists. A partial x-ray structure of the some-
what distantly related Rubulavirus, Newcastle disease
virus (NDV) F protein extracellular domain (ECD)
[33,34] has been used to build a model of the HRSV F pro-
tein ECD [35,36]. More recently, the complete x-ray struc-
ture of the extracellular domain of the F protein of human
parainfluenza virus 3 (hPIV3) has been solved [37]. The
mature F protein of human respiratory syncytial virus
(HRSV) contains fifteen cysteine residues that are abso-
lutely conserved in all known isolates of both A & B sub-
groups of HRSV and BRSV and are highly conserved
among the F proteins of the other Pneumoviruses such as
pneumonia virus of mice (PVM), as well as in the Metap-
neumoviruses, human metapneumovirus (HMPV), and
avian pneumovirus (APV) [38], and the F proteins of
other paramyxoviruses including the well studied New-
castle disease virus (NDV) and Sendai virus [39,40] F pro-
teins (Figure 2). No studies detailing the contribution of
these cysteine residues to the structure or function of the
HRSV F protein have been reported. The N-terminal signal
peptide contains a single cysteine residue, however this
region is removed by processing and is not present in the
mature protein. A single cysteine residue is present in the
cytoplasmic tail (position 550) has been shown to be the
site of addition of a palmitoyl group in HRSV [41],
although the cytoplasmic tail has been shown to not be
required for cell fusion [42].
Diagram of the HRSV F protein Figure 1
Diagram of the HRSV F protein. A linear representation of the HRSV F precursor protein (A2 strain) is shown.  Amino 
acid positions of individual domains are indicated with residues numbered in the context of the full-length coding region.  
Disulfide linked F1 & F2 subunits are delineated with arrows.  The furin mediated cleavage sites are indicated by filed arrow-
heads.  The intervening cleavage fragment is indicated as a gray box.  Positions of the individual cysteine residues are depicted 
as asterisks.  Asparagine residues (N116 and N126) which are sites of N-linked glycosylation are represented with circles.  The 
site of palmitoylation at cysteine residue 550 is depicted as a jagged line.  SP = signal peptide; f = fusion peptide; HR1 = heptad 
repeat 1; HR2 = heptad repeat 2; TM = transmembrane region.  Figure adapted from [5].
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Alignment of paramyxoviral F proteins Figure 2
Alignment of paramyxoviral F proteins. Sequence alignment was performed as described in methods. Accession numbers 
for the sequences of the viral F proteins used for the alignment are as described in methods. Conserved cysteine residues are 
highlighted in yellow.
                    10        20        30        40        50        60        70        80        90        100       110       120 
           ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
HRSV       -----MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELS-NIK--KNKCNGTDAKVK--LIKQELDKYKNAVTELQLLMQSTQATNNRARRE 
BRSV       -----MATTAMRMIISIIFISTYVTHITLCQNITEEFYQSTCSAVSRGYLSALRTGWYTSVVTIELS-KIQ--KNVCKSTDSKVK--LIKQELERYNNAVVELQSLMQNEPASFSRAKRG 
PVM        ---------MIPGRIFLVLLVIFNTKPIHPNTLTEKFYESTCSVETAGYKSALRTGWHMTVMSIKLS-QIN--IESCKSSNS-----LLAHELAIYSSAVDELRTLSSN----------- 
HMPV       --------------MSWKVVIIFSLLITPQHGLKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVG-DVE--NLTCADGPS-----LIKTELDLTKSALRELRTVSADQLAR------- 
APV        --------------MSWKVVLLLVLLATPTGGLEESYLEESCSTVTRGYLSVLRTGWYTNVFTLEVG-DVE--NLTCTDGPS-----LIRTELELTKNALEELKTVSADQLAK------- 
hPIV3      -----MPT--------STLLIITTIIMASFCQIDITKLQHVGVLVNSPKGMKISQNFETRYLILSLIPKIE-DSNSCGDQQIKQYKRLLDRLIIPLYDGLRLQKDVIVTNQESNEN---- 
Sendai     -----MATYIQRVQCISALLSVVLTTLVS-CQIPRDRLSNIGVIVDEGKSLKIAGSHESRYIVLSLVPGID-LENGCGTAQVIQYKSLLNRLLIPLRDALDLQEALITVTNDTMTG---- 
Mumps      ------------MKVFLVTCLGFAVFSS-SVCVNINILQQIGYIKQQVRQLSYYSQSSSSYIVVKLLPNIQPTDNSCEFKSVTQYNKTLSNLLLPIAENINNIASPSSGSR--------- 
NDV        MGSRPFTKNPAPMMLTIRVALVLSCICP-ANSIDGRPFAAAGIVVTGDKAVNIYTSSQTGSIIVKLLPNLPKDKEACAKAPLDAYNRTLTTLLTPLGDSIRRIQESVTTSGG-------- 
SV5        ------------MGTIIQFLVVSCLLAG-AGSLDPAALMQIGVIPTNVRQLMYYTEASSAFIVVKLMPTIDSPISGCNITSISSYNATVTKLLQPIGENLETIRNQLIPTR--------- 
Measles    -----MGLKVNVSAIFMAVLLTLQTP---TGQIHWGNLSKIGVVGIGSASYKVMTRSSHQSLVIKLMPNIT-LLNNCTRVEIAEYRRLLRTVLEPIRDALNAMTQNIRPVQSVA------ 
Rinderpest ------------MKILFATLLVVTTPHLVTGQIHWGNLSKIGVVGTGSASYKVMTQSSHQTLVIKLMPNIT-AIDNCTKTEIEEYKRLLGTVLQPIKVALNAITKNIKPIRSST------ 
Nipah      ----MVVILDKRCYCNLL-ILILMISECSVGILHYEKLSKIGLVKGVTRKYKIKSNPLTKDIVIKMIPNVS-NMSQCTGSVMENYKTRLNGILTPIKGALEIYKNNTHDLVG-------- 
Hendra     -----MATQEVRLKCLLCGIIVLVLSLEGLGILHYEKLSKIGLVKGITRKYKIKSNPLTKDIVIKMIPNVS-NVSKCTGTVMENYKSRLTGILSPIKGAIELYNNNTHDLVG-------- 
                    130       140       150       160       170       180       190       200       210       220       230       240 
           ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
HRSV       LPRFMNYTLNNAKKTNVTLSKKRKRRFLG--FLLGVG--SAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLPIVNKQSCSISNIETVIEFQQK 
BRSV       IPELIHYTRNSTKKFYGLMGKKRKRRFLG--FLLGIG--SAVASGVAVSKVLHLEGEVNKIKNALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKELLPQVNNHDCRISNIETVIEFQQK 
PVM        ----------------ALKSK-RKKRFLG--LILGLG--AAVTAGVALAKTVQLESEIALIRDAVRNTNEAVVSLTNGMSVLAKVVDDLKNFISKELLPKINRVSCDVHDITAVIRFQQL 
HMPV       --E-------------EQIENPRQSRFVLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRELKDFVSKNLTRAINKNKCDIADLKMAVSFSQF 
APV        --E-------------ARIMSPRKARFVLGAIALGVATAAAVTAGVAIAKTIRLEGEVAAIKGALRKTNEAVSTLGNGVRVLATAVNDLKDFISKKLTPAINRNKCDISDLKMAVSFGQY 
hPIV3      ----------------TNPRTKRFFGGVIGTIALGVATSAQITAAVALVEAKQARSDIEKLKEAIRDTNKAVQSVQSSIGNLIVAIKSVQDYVNKEIVPSIARLGCEAAGLQLGIALTQH 
Sendai     ----------------ADVPQSRFFGAVIGTIALGVATSAQITAGIALAEAREAKRDIALIKESMTKTHKSIELLQNAVGEQILALKTLQDFVNDEIKPAISELGCETAALRLGIKLTQH 
Mumps      -------------------RHKRFAGIAIGIAALGVATAAQVTAAVSLVQAQTNARAIAAMKNSIQATNRAVFEVKEGTQRLAIAVQAIQDHINTIMNTQLNNMSCQILDNQLATSLGLY 
NDV        ------------------GRQGRLIGAIIGGVALGVATAAQITAAAALIQAKQNAANILRLKESIAATNEAVHEVTDGLSQLAVAVGKMQQFVNDQFNKTAQELDCIKIAQQVGVELNLY 
SV5        -------------------RRRRFAGVVIGLAALGVATAAQVTAAVALVKANENAAAILNLKNAIQKTNAAVADVVQATQSLGTAVQAVQDHINSVVSPAITAANCKAQDAIIGSILNLY 
Measles    ----------------SSRRHKRFAGVVLAGAALGVATAAQITAGIALHQSMLNSQAIDNLRASLETTNQAIEAIRQAGQEMILAVQGVQDYINNELIPSMNQLSCDLIGQKLGLKLLRY 
Rinderpest ----------------TSRRHRRFAGVALAGAALGVATAAQITAGIALHQSMMNTQAIESLKASLETTNQAIEEIRQAGQEMILAVQGVQDYINNELVPAMGQLSCDIVGQKLGLKLLRY 
Nipah      --------------------DVRLAGVIMAGVAIGIATAAQITAGVALYEAMKNADNINKLKSSIESTNEAVVKLQETAEKTVYVLTALQDYINTNLVPTIDKISCKQTELSLDLALSKY 
Hendra     --------------------DVKLAGVVMAGIAIGIATAAQITAGVALYEAMKNADNINKLKSSIESTNEAVVKLQETAEKTVYVLTALQDYINTNLVPTIDQISCKQTELALDLALSKY 
                    250       260       270       280       290       300       310       320       330       340       350       360 
           ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
HRSV       NNRLLEITREFSVNAGVT--TPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCD 
BRSV       NNRLLEIAREFSVNAGIT--TPLSTYMLTNSELLSLINDMPITNDQKKLMSSNVQIVRQQSYSIMSVVKEEVIAYVVQLPIYGVIDTPCWKLHTSPLCTTDNKEGSNICLTRTDRGWYCD 
PVM        NKRLLEVSREFSSNAGLT--HTVSSFMLTDRELTSIVGGMAVSAGQKEIMLSSKAIMRRNGLAILSSVNADTLVYVIQLPLFGVMDTDCWVIRSSIDCHN--IADKYACLARADNGWYCH 
HMPV       NRRFLNVVRQFSDNAGIT--PAISLDLMTDAELARAVSNMPTSAGQIKLMLENRAMVRRKGFGFLIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSG--KKGNYACLLREDQGWYCQ 
APV        NRRFLNVVRQFSDNAGIT--PAISLDLMTDAELVRAVSNMPTSSGQINLMLENRAMVRRKGFGILIGVYGSSVVYIVQLPIFGVIDTPCWKVKAAPLCSG--KDGNYACLLREDQGWYCQ 
hPIV3      YSELTNIFGDNIGSLQEKGIKLQGIASLYRTNITEIFTTSTVDKYDIYDLLFTESIKVR---VIDVDLNDYSITLQVRLPLLTRLLNTQIYKVDSISYNI----HNREWYIPLPS--HIM 
Sendai     YSELLTAFGSNFGTIGEKSLTLQALSSLYSANITEIMTTIRTGQSNIYDVIYTEQIKGT---VIDVDLERYMVTLSVKIPILSEVPGVLIHKASSISYNI----DGEEWYVTVPS--HIL 
Mumps      LTELTTVFQPQLINPALSPISIQALRSLLGSMTPAVVQATLSTSISAAEILSAGLMEGQ---IVSVLLDEMQMIVKINIPTIVTQSNALVIDFYSISSFI----NNQESIIQLPD--RIL 
NDV        LTELTTVFGPQITSPALNKLTIQALYNLAGGNMDYLLTKLGIGNNQLSSLIGSGLITGN---PILYDSQTQLLGIQVTLPSVGNLNNMRATYLETLSVST----TRGFASALVPK--VVT 
SV5        LTELTTIFHNQITNPALSPITIQALRILLGSTLPTVVEKSFNTQISAAELLSSGLLTGQ---IVGLDLTYMQMVIKIELPTLTVQPATQIIDLATISAFI----NNQEVMAQLPT--RVM 
Measles    YTEILSLFGPSLRDPISAEISIQALSYALGGDINKVLEKLGYSGGDLLGILESRGIKAR---ITHVDTESYFIVLSIAYPTLSEIKGVIVHRLEGVSYNI----GSQEWYTTVPK--YVA 
Rinderpest YTEILSLFGPSLRDPISAEISIQALSYALGGDINKILEKLGYSGSDLLAILESKGIKAK---ITYVDIESYFIVLSIAYPSLSEIKGVIIHRLEGVSYNI----GSQEWYTTVPR--YVA 
Nipah      LSDLLFVFGPNLQDPVSNSMTIQAISQAFGGNYETLLRTLGYATEDFDDLLESDSITGQ---IIYVDLSSYYIIVRVYFPILTEIQQAYIQELLPVSFNN----DNSEWISIVPN--FIL 
Hendra     LSDLLFVFGPNLQDPVSNSMTIQAISQAFGGNYETLLRTLGYATEDFDDLLESDSIAGQ---IVYVDLSSYYIIVRVYFPILTEIQQAYVQELLPVSFNN----DNSEWISIVPN--FVL 
                    370       380       390       400       410       420       430       440       450       460       470       480 
           ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
HRSV       NAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEG 
BRSV       NAGSVSFFPQTETCKVQSNRVFCDTMNSLTLPTDVNLCNTDIFNTKYDCKIMTSKTDISSSVITSIGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKLEG 
PVM        NAGSLSYFPSPTDCEIHNGYAFCDTLKSLTVPVTSRECNSNMYTTNYDCKISTSKTYVSTAVLTTMGCLVSCYGHNSCTVINNDKGIIRTLPDGCHYISNKGVDRVQVGNTVYYLSKEVG 
HMPV       NAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCKVSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTVTIDNTVYQLSKVEG 
APV        NAGSTVYYPNEEDCEVRSDHVFCDTAAGINVAKESEECNRNISTTKYPCKVSTGRHPISMVALSPLGALVACYDGMSCSIGSNKVGIIRPLGKGCSYISNQDADTVTIDNTVYQLSKVEG 
hPIV3      TKGAFLGGADVKECIEAFSSYICPSDPGFVLNHEMESC---LSGNISQCPRTTITSDIVPRYAFVNGGVVANCITTTCTCNGIGNRINQPPNQGVKIITHKECSTIGINGMLFNTN--KE 
Sendai     SRASFLGGANIADCVESRLTYICPRDPAQLIPDSQQKC---ILGDTTRCPVTKVVDNIIPKFAFVNGGVVANCIASTCTCGTGRRPISQDRSKGVVFLTHDNCGLIGVNGIELYAN--RK 
Mumps      EIGNEQWSYPAKNCKLTRHHIFCQYNEAERLSLESKLC---LAGNISACVFSPIAGSYMRRFVALDGTIVANCRSLTCLCKSPSYPIYQPDHHAVTTIDLTACQTLSLDGLDFSIV--SL 
NDV        QVGSVIEELDTSYCIETDLDLYCTRIVTFPMSPGIYSC---LSGNTSACMYSKTEGALTTPYMTIKGSVIANCKMTTCRCVNPPGIISQNYGEAVSLIDKQSCNVLSLGGITLRLS--GE 
SV5        VTGSLIQAYPASQCTITPNTVYCRYNDAQVLSDDTMAC---LQGNLTRCTFSPVVGSFLTRFVLFDGIVYANCRSMLCKCMQPAAVILQPSSSPVTVIDMYKCVSLQLDNLRFTIT--QL 
Measles    TQGYLISNFDESSCTFMPEGTVCSQNALYPMSPLLQEC---LRGSTKSCARTLVSGSFGNRFILSQGNLIANCASILCKCYTTGTIINQDPDKILTYIAADHCPVVEVNGVTIQVGSRRY 
Rinderpest TQGYLISNFDDTPCAFSPEGTICSQNALYPMSPLLQEC---FRGSTRSCARTLVSGSIGNRFILSKGNLIANCASILCKCYTTGSIISQDPDKILTYIAADQCPIVEVDGVTIQVGSREY 
Nipah      VRNTLISNIEIGFCLITKRSVICNQDYATPMTNNMREC---LTGSTEKCPRELVVSSHVPRFALSNGVLFANCISVTCQCQTTGRAISQSGEQTLLMIDNTTCPTAVLGNVIISLG--KY 
Hendra     IRNTLISNIEVKYCLITKKSVICNQDYATPMTASVREC---LTGSTDKCPRELVVSSHVPRFALSGGVLFANCISVTCQCQTTGRAISQSGEQTLLMIDNTTCTTVVLGNIIISLG--KY 
                    490       500       510       520       530       540       550       560       570       580       590       600 
           ---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+---------+ 
HRSV       KSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVN--AGKSTTNIMITTIIIVIIVILLSLIAVGLLLYCKARSTP-----------VTLSKDQLSGINNIA 
BRSV       KALYIKGEPIINYYDPLVFPSDEFDASIAQVNAKINQSLAFIRRSDELLHSVD--VGKSTTNVVITTIIIVIVVVILMLIAVGLLFYCKTKSTP-----------IMLGKDQLSGINNLS 
PVM        KSIVVRGEPLVLKYDPLSFPDDKFDVAIRDVEHSINQTRTFLKASDQLLDLSENRENKNLNKSYILTTLLFVVMLIIIMAVIGFILYKVLKMIRD----------NKLKSKSTPGLTVLS 
HMPV       EQHVIKGRPVSSSFDPVKFPEDQFNVALDQVFESIENSQALVDQSNRILSSAE----KGNTGFIIVIILIAVLGSTMILVSVFIIIKKTKKPTG--------------APPELSGVTNNG 
APV        EQHTIKGKPVSSNFDPIEFPEDQFNIALDQVFESVEKSQNLIDQSNKILDSIE----KGNAGFVIVIVLIVLLMLAAVGVGVFFVVKKRKAAPK--------------FPMEMNGVNNKG 
hPIV3      GTLAFYTPDDITLNNSVALDPIDISIELNKAKSDLEESKEWIRKSNQKLDSIG--NWHQSSTTIIIILMMIIILFIINITIITIAIKYYR------------------IQKRNQMDQNDK 
Sendai     GHDATWGVQNLTVGPAIAIRPVDISLNLAAATDFLQDSRAELEKARKILSEVG--RWYNSGATLITIIVVMIVVLVVIIVIVIVLYRLRRSMLMSNPAGRISRDTYTLEPKIRHMYTNGG 
Mumps      SNITYAENLTISLSQTINTQPIDISTELSKVNASLQNAVKYIKESNHQLQSVN--VNSKIGAIIVAALVLSILSIIISLLFCCW-AYVATKEI----------RRINFKTNHINTISSSV 
NDV        FDVTYQKNISIQDSQVIITGNLDISTELGNVNNSISNALNKLEESNRKLDKVN--VKLTSTSALITYIVLTIISLVFGILSL----ILACYLM----------YKQKAQQKTLLWLGNNT 
SV5        ANVTYNSTIKLESSQILSIDPLDISQNLAAVNKSLSDALQHLAQSDTYLSAIT--SATTTSVLSIIAICLGSLGLILIILLS----VVVWKLL----------TIVVANRNRMENFVYHK 
Measles    PDAVYLHR--IDLGPPISLERLDVGTNLGNAIAKLEDAKELLESSDQILRSMK--GLSSTSIVYILIAVCLGGLIGIPALICCCRGRCNKKGE----------QVGMSRPGLKPDLTGTS 
Rinderpest PDAVYLHK--IDLGPPISLEKLDVGTNLGNAVTKLEKAKDLLDSSDLILETIK--GASVTNTGHILVGAGLIAVVGILIVTCCCRKRSNDSKV----------STVILNPGLKPDLTGTS 
Nipah      LGSVNYNSEGIAIGPPVFTDKVDISSQISSMNQSLQQSKDYIKEAQRLLDTVN--PSLISMLSMIILYVLSIASLCIGLITFISFIIVEKKRN----------TYSRLEDRRVRPTSSGD 
Hendra     LGSINYNSESIAVGPPVYTDKVDISSQISSMNQSLQQSKDYIKEAQKILDTVN--PSLISMLSMIILYVLSIAALCIGLITFISFVIVEKKRG----------NYSRLDDRQVRPVSNGD 
HRSV       FSN
BRSV       FSK                                                                                                                      
PVM
HMPV       FIPHN.                                                                                                                   
APV        FIP
hPIV3      PYVLTNK
Sendai     FDAMTEKR
Mumps      DDLIRY                                                                                                                   
NDV        LDQMRATTKM
SV5
Measles    KSYVRSL
Rinderpest KSYVRSL
Nipah      LYYIGT.
Hendra     LYYIGT.                                                                                                                 Virology Journal 2006, 3:34 http://www.virologyj.com/content/3/1/34
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To determine the contribution of the individual cysteine
residues in the extracellular domain (ECD) to its func-
tions, a panel of mutations in which each cysteine residue
in the ECD of the HRSV F protein (residues 37, 69, 212,
313, 322, 333, 343, 358, 367, 382, 393, 416, 422, 439)
was individually changed to a serine, and the effect of
these mutations upon the function of the HRSV F protein
was determined.
Results
To better understand our results, the molecular structure
of hRSV F protein was modeled using hPIV3 structure
[pdb code 1ztm] [37] as a template. The sequence align-
ment was essentially the same as previously described
[36] with a small adjustment of residues between 331 and
346 to allow all pairs of cysteine residues in the extracel-
lular domain to be positioned close enough to form
disulfide bonds. The trimer model of RSV F protein was
constructed using Modeler software (Accelrys, CA) with-
out further refinement. The resulting predicted disulfide
bond pattern is 37–439, 69–212, 322–333, 313–343,
358–367, 382–393, and 416–422 (Figure 3).
To assess the effect of the cysteine mutations on protein
expression, 293T cells were transfected with plasmids
encoding either the wild-type F protein or those contain-
ing the individual cysteine mutations followed by meta-
bolic labeling with [35S]-methionine-cysteine mixture.
Cell lysates were prepared and immunoprecipitated with
a cocktail of four anti-HRSV F mAbs (palivizumab, 47F,
Mab19, and 101F) directed against the two major anti-
genic sites II and IV, V, VI [43] as previously described
Computer model of the HRSV F protein Figure 3
Computer model of the HRSV F protein. The molecular structure of HRSV F protein ECD was modeled using the human 
parainfluenza virus 3 virus F protein ECD structure as template as described in methods. Ribbon diagrams of the F1-F2 mono-
mer (left) and F protein homotrimer (right) are shown. Heptad repeat 1 (HR1) and heptad repeat 2 (HR2) are indicated with 
arrows. Cysteine residues are depicted as yellow balls with specific residue disulfide pairs indicated on the monomer.
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[44]. Levels of total immunoprecipitated F protein as well
as the degree of cleavage of the F0 precursor into the F1
and F2 subunits were determined (Figure 4). A non-HRSV
F related cellular band (present in lysates from cells trans-
fected with empty vector (-) or beta-galactoside expression
vector negative controls) that migrated slightly slower
than the F0 precursor was also immunoprecipitated under
these conditions. As shown in figure 4, mutation of extra-
cellular cysteine residues 212, 382, 422 had little to no
discernable effects on the levels of total immunoprecipi-
tated protein or the degree of F0 cleavage relative to those
observed for the wild-type HRSV F protein. Furthermore,
the bands corresponding to the F1 and F2 subunits
derived from these mutations migrated similarly to those
from the wild-type HRSV F protein suggesting that these
mutations had no gross effect on glycosylation. These
findings are intriguing given that these three cysteine resi-
dues are absolutely conserved not only in the F proteins of
other Pneumovirinae, but also in the F proteins of the Par-
amyxovirinae as well (Figure 2). In contrast, mutation of
cysteine residues 37, 313, 333, 343, 358, 367, 393, 416, or
439 to serine all dramatically reduced or abolished the
levels of total F protein immunoprecipitated as well as the
degree of F0 precursor cleavage as determined by the lev-
els of F1 and F2. These results suggest that either mutation
of these cysteine residues to serine grossly affected the
translation or folding of the F protein such that it was
unstable or rapidly degraded, or that these mutations
reduced the efficiency of binding of the four antibodies
used in the immunoprecipitation. Based upon the model,
Immunoprecipitation of HRSV F cysteine mutations Figure 4
Immunoprecipitation of HRSV F cysteine mutations. 293T cells were mock transfected (-), transfected with a plasmid 
expressing beta-galactosidase (b-gal), or plasmids encoding the wild-type (WT) HRSV F protein or various cysteine mutants 
(listed above lanes), followed by metabolic labeling with [35S]-methionine/cysteine mixture, and immunoprecipitation as 
described in [44].  The positions of molecular weight size markers are indicated.  The positions of the F1 and F2 subunits are 
indicated with arrows. 
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residues 382 and 422 form disulfide bonds with residues
393 and 416 respectively. It is intriguing that mutation of
one residue in the pair has no effect, while mutation of its
bond partner residue has a dramatic effect. Together, these
data would suggest that the formation of a disulfide bond
between residues 382 and 393 or 416 and 422 is not
required, but rather suggests the presence of a cysteine res-
idue at positions 393 and 416 is critical. It is possible that
loss of a disulfide partner in one case leads to aberrant
disulfide bond formation by that free cysteine, while in
the other case, the cysteine remains free and unbonded.
Further work is needed to clarify the exact effect of such
mutations. As these antibodies have been shown to recog-
nize largely non-conformational epitopes [43,45], it
would be unlikely to have a simultaneous loss of binding
to both antigenic sites, thus we favor the interpretation
that these cysteine mutations disrupted proper global pro-
tein folding and stability. Very low levels of F1 and F2
were observed with mutations C69S and C322S. Mutation
C313S resulted in the appearance of a novel immunopre-
cipitating band migrating at approximately 45 kDa sug-
gesting altered proteolytic cleavage or truncated
translation. Further analysis is required to determine the
exact nature of this band. Mutation of cysteine 69 to serine
(C69S) reduced, but did not abolish expression or protein
cleavage. These results suggest that mutation of cysteine
residues 212, 382, and 422 did not disrupt folding suffi-
ciently to affect processing of F0 to F1 and F2. Mutation of
residues 69 and 322 dramatically reduced the levels of
total protein immunoprecipitated as well the levels of F0
processed to F1 and F2. None of the mutations appeared
to grossly affect glycosylation as the F0 and F1 and F2 sub-
units of all the cysteine mutations migrated similarly,
although our gel system would not allow resolution of
minor changes in glycosylation.
To determine the role of the individual cysteine residues
in cell surface expression, 293T cells transfected with plas-
mids expressing either wild-type HRSV F or the panel of
cysteine mutations were analyzed by ELISA using palivi-
zumab under either permeabilizing (to measure total pro-
tein) or non-permeabilizing (to measure cell-surface
only) conditions. Values were calculated as percents rela-
tive to wild-type HRSV F after adjusting for background
signal from the vector only control. As shown in Figure 5,
cysteine mutations C212S, C382S, and C422S had similar
levels of cell surface expression levels as wild-type HRSV F
protein. Mutation of cysteine 69 to serine (C69S) reduced
both total and cell surface expression by 25% and 72%
respectively, but did not abolish expression or protein
processing. Similar to the metabolic labeling results show-
ing reduced total protein levels, mutations C37S, C313S,
C322S, C333S, C343S, C358S, C367S, C393S, C416S,
and C439S all had reduced levels of total protein (perme-
abilizing conditions) ranging from 49–92% reduction rel-
ative to wild-type F protein (Table 1). However, when the
level of cell surface expression was examined by ELISA
under non-permeabilizing conditions, all mutations had
either low (8% for C393S, 3% for C313S) or no detectable
levels of cell surface protein. This finding suggests that res-
idues 37, 313, 322, 333, 343, 358, 367, 393, 416, and 439
are critical for cell surface expression most likely through
their role in proper protein folding and disulfide bond
formation. These results also suggest that the reduction in
cell surface binding by the antibodies used in this study is
not due to a diminished ability of these antibodies to rec-
ognize the cysteine mutations, as in several cases, F pro-
tein was clearly detected under permeabilizing conditions
(Figure 5, C37S, C313S, C322S, C333S, C343S, C358S,
C393S, C416S, C439S), but little to no F protein was
detected under non-permeabilizing conditions. However,
these results obtained using this assay can not rule out the
possibility that in instances where cell surface F protein
was not detected (under non-permeabilizing conditions),
the protein encoded by these mutations was misfolded in
such a way as to block the epitope recognized by the anti-
body.
To extend these results, the effect of the cysteine muta-
tions upon the level of cell surface expression was exam-
ined by flow cytometry using four different antibodies,
47F [46], 101F (a monoclonal which recognizes the site
IV, V, VI region), palivizumab [47] or mAb19 [48]
directed against one of two major antigenic sites (II or IV,
Expression of cysteine mutations measured by ELISA Figure 5
Expression of cysteine mutations measured by 
ELISA. 293T cells were transfected with plasmids encoding 
the wild-type HRSV F (WT), empty vector cassette (EV) or 
the various cysteine mutants (listed below lanes), followed by 
fixation and analysis using an ELISA as described in methods. 
Results are presented relative to values obtained with wild-
type HRSV F which was set at 100%, and represent the aver-
age of three separate determinations. Results obtained using 
permeabilizing conditions are depicted with open bars. 
Results obtained using non-permeabilizing conditions are 
depicted with a solid bars.
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V, VI) in the F protein. Consistent with results obtained
using ELISA under non-permeabilizing conditions, flow
cytometry analysis demonstrated that mutation of
cysteine residues 37, 313, 322, 333, 343, 358, 367, 393,
416, and 439 reduced binding of all four antibodies,
while mutation of cysteine mutants C382S, and C422S
retained similar levels of antibody binding as the wild-
type F protein (Table 1). As the same set of cysteine muta-
tions that reduced or abolished F0 protein cleavage and
cell surface expression, also reduced or abolished cell sur-
face binding of the four mAbs tested here, we conclude
that cysteine residues 37, 313, 322, 333, 343, 358, 367,
393, 416, and 439 play a key role in the proper folding,
processing, and cell surface transport of the HRSV F pro-
tein. Again, as the epitopes of these antibodies are directed
against two different antigenic regions of F protein and
have been shown to be largely non-conformational
[43,45], we suggest that it is unlikely that the inability to
detect these cysteine mutation F proteins on the cell sur-
face is attributable to protein misfolding which would
simultaneously block the epitopes recognized by these
four different antibodies, but rather reflects a true defect in
cell surface transport caused by these mutations. Interest-
ingly, mutation of residue C212, which had wild-type lev-
els of protein expression as determined by ELISA,
appeared to have somewhat reduced levels of cell surface
protein (37–47% of wild-type) as determined by flow
cytometry. Although the exact reason for this is not clear,
it could reflect a sensitivity of this particular mutant (fold-
ing, reactivity to fixation agent, etc.) to the differences in
the experimental conditions used for ELISA and flow
cytometry.
To assess the functionality of these cysteine mutations, a
cell fusion assay was used as previously described [44]. As
mutation of cysteine residues in other viral fusion pro-
teins has been reported to cause a temperature-sensitive
(ts) phenotype [49], we also examined the fusion activity
of the panel of cysteine mutations at 32°C and 39.5°C as
HRSV mutants sensitive for these two temperatures have
been previously described [50,51]. The overall levels of
wild-type HRSV F-mediated cell fusion are reduced by
approximately 50% at either 32°C or 39.5°C relative to
37°C [42]. As shown in figure 6, mutation of cysteine res-
idues 37, 69, 313, 322, 333, 343, 358, 367, 393, 416, and
439 reduced cell fusion activity to similar levels as a previ-
ously described point mutation in the fusion peptide
region (pL138R) [44]. In contrast, mutations C382S and
C422S had cell fusion activity equivalent to wild-type
HRSV F protein. Mutation of cysteine residue 212 reduced
fusion activity by 40–50%. This finding correlates with
the reduced cell surface expression observed using flow
Table 1: Summary of results for HRSV F cysteine mutants. Processing is defined as relative amounts of F0, F1, and F2, and is described 
as being equivalent to wild-type HRSV F protein (complete) or reduced. Cell surface and total expression were measured by ELISA 
under permeabilizing (total F protein) or non-permeabilizing (cell surface F protein) conditions using palivizumab as described in 
methods and reported as percent relative to wild-type HRSV F protein. Reactivity with neutralizing mAbs (palivizumab, Mab19, 47F, 
and 101F) as determined by flow cytometry is shown and reported as percent relative to wild-type HRSV F protein. Cell fusion activity 
is reported as luciferase activity measured at 32°C, 37°C, and 39.5°C as described in [44]. All values are expressed as % relative to wild-
type at the respective temperatures.
Protein 
Processin
g
ELISA Cell surface expression (Flow 
cytometry)
Cell fusion (% of WT)
Cell surface 
protein (Non-
permeabilized)
Total protein 
(permeabilized
)
Palivizu
mab
47F 101F mAb19 32°C 37°C 39.5°C
Wild-type complete 100 100 100 100 100 100 100% 100% 100%
C37S minimal 0.00 51 7 3 2 4 8% 8% 12%
C69S reduced 25 72 22 19 21 20 10% 12% 12%
C212S complete 117 103 37 43 46 39 52% 44% 34%
C313S reduced 3 44 23 11 4 1 6% 5% 5%
C322S minimal 0 35 5 1 3.5 0 7% 5% 6.5%
C333S minimal 0 41 8 3 3 0.5 12% 8.5% 10%
C343S minimal 0 22 4 0 1.5 0 14% 17% 19%
C358S minimal 0 17 3 0 2 0 7% 4% 6%
C367S minimal 0 8 8 3 9 1.5 10% 8% 9%
C382S complete 103 90 86 102 96 88 105% 91% 100%
C393S reduced 8 42 13 10 13 7 14% 10% 12%
C416S minimal 0 43 4 3 5 0 5.5% 4% 4%
C422S complete 141 132 90 93 81 81 140% 122% 146%
C439S minimal 0.4 26 7 4 4 1 50% 29% 30%Virology Journal 2006, 3:34 http://www.virologyj.com/content/3/1/34
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cytometry. Although the absolute levels of HRSV F-medi-
ated cell fusion were reduced at both 32°C and 39.5°C
relative to 37°C for all proteins including wild-type (Fig-
ure 6), there were no differences observed in their relative
fusion activities of the cysteine mutations at either 32°C
and 39.5°C suggesting a lack of a gross ts phenotype for
fusion for any of these mutations (Figure 4B).
Discussion
Limited direct structure-function data exists for the HRSV
F protein. This study utilizes a genetic approach to analyze
the contribution of the individual cysteine residues in the
extracellular domain in protein expression and cell fusion
of the HRSV F protein and represents the first analysis of
the contribution of the cysteine residues of the HRSV F
protein ECD to its function. Generally, cysteine residues
are critical for folding and provide structural stability to a
protein via the formation of disulfide bonds. Mutation of
cysteine residues 37, 313, 322, 333, 343, 358, 367, 393,
416, and 439 abolished or reduced cell surface expression
to less than 7% of wild type HRSV F protein. This suggests
that these residues play a key role in the proper folding
and subsequent transport through the Golgi to the cell
surface. Identification of the stages at which these specific
cysteine mutations block the folding, maturation, and
transport of the HRSV F protein is currently ongoing.
Mutation of cysteine residues can often lead to a tempera-
ture sensitive (ts) phenotype such as that observed for the
herpes simplex type 1 gD glycoprotein [49]. The lack of an
observable ts phenotype in this study is supported by the
high thermostability of the HRSV F protein among para-
myxoviruses [27].
From direct mapping of disulfide bonds in Sendai virus
[39], and based upon the positional conservation of the
cysteine 69 residue in the HRSV F proteins with that of
Sendai virus F protein and the F proteins from other of the
Paramyxoviridae, it is likely that cysteine residues 69 and
212 participate in the disulfide linkage between the F1
and F2 subunits. The Pneumovirinae members have a posi-
tionally conserved second cysteine residue in the F2 subu-
nit (corresponds to residue 37 in HRSV F protein) (Figure
2) not found in the other Paramyxovirinae. In the model of
the HRSV F ECD, this cysteine residue is predicted to make
a disulfide bond with cysteine residue 439, which is also
only conserved in the F proteins of the Pneumovirinae
members and not found in the F proteins of the other Par-
amyxovirinae  members. This would suggest that two
disulfide bonds are formed between the F1 and F2 subu-
nits. We are currently performing direct biochemical map-
ping of the disulfide linkages to formally demonstrate
this. This could explain, in part, the unique thermostabil-
ity described for the HRSV F protein ECD [27].
HRSV is a significant human pathogen, and the F protein
has been identified as the target of multiple neutralizing
antibodies [47,52,53] as well as small molecule inhibitors
[54-58]. As such, the HRSV F protein represents a critical
viral target for the development of new and improved pre-
ventions and treatments for HRSV induced disease. A
greater understanding of its structure-function relation-
ships would greatly facilitate the development of these
new agents. The results of this study provide further sup-
port that the highly conserved HRSV F protein cysteine
residues play a critical role in the structure and function of
this protein. As disulfide bonds have been shown to play
roles beyond proper protein folding and stabilization of
protein structure [59], it is tempting to speculate that, sim-
ilar to HIV [60], the disulfide bonds of the Pneumovirus F
proteins may have a direct role in fusion. Our modeling
and analysis suggest the presence of two disulfide bonds
which join the F1 and F2 subunits of the HRSV F protein.
If formally demonstrated, this would highlight a distinct
structural feature of the F proteins of the Pneumovirinae
not described for the F proteins of the Paramyxovirinae.
Methods
Cells, plasmids and transfections
293T cells were grown at 37°C in a humidified atmos-
phere of 5% CO2 and maintained in Dulbecco's modified
Eagle media (DMEM) with 4 mM L-glutamine adjusted to
contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose and
10% FBS. Cells were tested and confirmed to be free of
mycoplasma contamination. Plasmid pHRSVFoptA2,
Fusion activity of cysteine mutations Figure 6
Fusion activity of cysteine mutations. 293T cells were 
transfected with plasmids encoding either the wild-type 
HRSV F protein or the panel of cysteine mutants and fusion 
activity was measured at 32°C, 37°C, or 39.5°C as described 
in [44]. Fusion activity is represented as relative light units 
(RLUs), and values represent the average of three separate 
determinations.
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which expresses the HRSV F protein of the A2 strain whose
sequence was codon optimized and derived from a
known infectious HRSV cDNA [61], has been previously
described [44] and served as the template for the genera-
tion of the panel of cysteine mutations by site directed
mutagenesis using the QuikChange® Site-Directed Muta-
genesis kit (Stratagene®, La Jolla, CA). Cells were tran-
siently transfected using FuGENE 6 reagent (Roche
Applied Science, IN) as previously described [44].
Metabolic labeling and immunoprecipitation
[35S]-methionine/cysteine radiolabeled cell lysates were
prepared and immunoprecipitated with a cocktail of four
anti-HRSV F mAbs (palivizumab, 47F, Mab19, and 101F)
directed against the two major antigenic sites II and IV, V,
VI [43] as previously described [44].
ELISA
The binding of neutralizing monoclonal antibodies
(mAbs) to HRSV F protein was assayed by ELISA using
293T cells transiently transfected with plasmids express-
ing either wild-type F protein, the panel of cysteine
mutants, or a vector only control. 293T cells (2.0 × 104
cells/well) were plated the day before transfection in 96-
well plates in DMEM, supplemented with 1.5 gms./liter
sodium bicarbonate and 10% FBS. A total of 50 ngs of
plasmid DNA was complexed with 0.15 μl of FuGENE 6
reagent and incubated 20 minutes room temperature in
OptiMEM reduced-serum medium prior to addition to
cells in serum containing medium. At 20–24 hours post-
transfection, cells were assayed for binding of palivizu-
mab under permeabilizing or non-permeabilizing condi-
tions. Cells were fixed by the addition of 0.05%
glutaraldehyde (Sigma) in 1X PBS for 15 minutes at room
temperature. Cells were then either washed under condi-
tions which permeabilizing (0.1% Triton-X100 in PBS) or
non- permeabilizing (0.05% Tween-20 in PBS) condi-
tions. These conditions were verified using an anti-RSV N
protein mAb (clone # M291207, Fitzgerald Industries
International, Concord, MA) and HRSV infected cells.
HRSV N protein is only produced within the cytoplasm of
HRSV infected cells. The anti-N mAb yields a strong posi-
tive signal on infected cells when the wash buffer contain-
ing 0.1% Triton-X100 is used, but not when wash buffer
containing 0.05% Tween 20 is used (data not shown).
Cells were blocked for one hour with SuperblockTM
(Pierce Biotechnology, Inc., Rockford, IL) followed by
incubation with either 1 μg/ml chimeric 101F IgG, 1 μg/
ml palivizumab or a 1:600 dilution of mAb19 hybridoma
supernatant for one hour at room temperature. Samples
were then incubated with an anti-human IgG-HRP or an
anti-mouse IgG-HRP as appropriate (Amersham Bio-
sciences, Inc.) at 1:800 for one hour at room temperature
followed by detection with TMB substrate (Sigma, Inc.).
The reaction was stopped with the addition of 2N sulfuric
acid, and the optical density at 450 nm was read. Values
were calculated as percents relative to wild-type HRSV F
after adjusting for background signal from the vector only
control.
Flow cytometry
To confirm cell surface expression, 293T cells were trans-
fected with plasmids expressing either wild-type F protein,
the panel of cysteine mutants or a vector only control in
either 6-well or 96-well formats as described above. Cells
were fixed with 2% paraformaldehyde in PBS for 15 min-
utes at 4°C. Cells were washed with PBS containing 2%
FBS and then stained with either a chimerized human ver-
sion of 101F (murine V region grafted onto human IgG1κ
framework) or palivizumab (IgG1κ) at 1 μg/ml with an
anti-human IgG-Alexa-Fluor-488 conjugated secondary
(Molecular Probes, Eugene, OR) for analysis with the
FACSCalibur (BD Bisociences) and determining the mean
fluorescence intensity. Data analysis was performed with
Cell Quest and FloJo Analysis Software. Values were calcu-
lated as percents relative to wild-type HRSV F after adjust-
ing for background signal from the vector only control.
Cell fusion assays
Cell fusion assays were conducted as previously described
[44]. Briefly, one population of 293T cells was co-trans-
fected with pHRSVFOptA2 and pBD-NFκB (effectors
cells), and another population of 293T cells was trans-
fected with the pFR-Luc luciferase reporter plasmid
(reporter cells). At 24 hours post transfection, effector
cells were mixed with an equal amount of reporter cells in
a 96-well plate and incubated an additional 24 hours
prior to measurement of luciferase activity using the
Steady Glo Luciferase reporter system (Promega, Inc.).
Computer modeling
The molecular structure of HRSV F protein ECD was mod-
eled using the human parainfluenza virus 3 virus F protein
ECD structure as template [pdb code 1ztm], essentially in
the same way as previously described [36] with a small
adjustment of the residues between 331 and 346, thus
allowing all pairs of cysteine residues to be positioned
close enough to form disulfide bonds. Sequence align-
ment was carried out in ICM (Molsoft, CA) and manually
adjusted. The monomer molecular model was first gener-
ated in ICM and then the trimer was assembled.
Sequence alignment
Sequence alignment was performed using the CLUSTAL
W method in MegAlign program (version 5.05) from
DNASTAR, Inc. (Madison, WI). Genbank accession num-
bers for the sequences of the viral F proteins used for the
alignment are: HRSV [61], BRSV (NC_001989), PVM
(AY729016), HMPV (NC_004148), APV (AY590688),
hPIV3 (NC_001796), Sendai virus (NC_001552), MumpsVirology Journal 2006, 3:34 http://www.virologyj.com/content/3/1/34
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virus (NC_002200), NDV (AF309418), Simian parainflu-
enza virus 5 (SV5) (NC_006430), Measles virus (P69353),
Rinderpest virus (NC_006296), Nipah virus
(NC_002728), Hendra virus (NC_001906).
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